John David Trzupek, Arlington, MA (US); Katherine Lin Lee, West Newton, MA (US); Mark Edward Bunnage, Concord, MA (US); Seungil Han, Mystic, CT (US); David Hepworth, Concord, MA (US); Frank Eldridge Lovering, Acton, MA (US); John Paul Mathias, Concord, MA (US); Nikolaos Papaioannou, Newton, MA (US); Betsy Susan Pierce, East Lyme, CT (US); Joseph Walter Strohbach, Wentzville, MO (US); Stephen Wayne Wright, Old Lyme, CT (US); Christoph Wolfgang Zapf, Marlborough, MA (US); Lori Krim Gavrin, Villanova, PA (US); Arthur Lee, San Carlos, CA (US); David Randolph Anderson, Salem, CT (US); Kevin Joseph Curran, Somerset, NJ (US); Christoph Martin Dehnhardt, Burnaby (CA); Eddine Saiah, Brookline, MA (US); Joel Adam Goldberg, New Orleans, LA (US); Xiaolun Wang, San Diego, CA (US); Horng-Chih Huang, Chesterfield, MO (US); Richard Vargas, Bedford, MA (US); Michael Dennis Lowe, White Plains, NY (US); and Akshay Patny, Waltham, MA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Aug. 18, 2020, as Appl. No. 16/996,117.
Application 16/996,117 is a continuation of application No. 16/411,679, filed on May 14, 2019, granted, now 10,793,579.
Application 16/411,679 is a continuation of application No. 15/862,691, filed on Jan. 5, 2018, granted, now 10,329,302, issued on Jun. 25, 2019.
Application 15/862,691 is a continuation of application No. 15/232,892, filed on Aug. 10, 2016, granted, now 9,879,022, issued on Jan. 30, 2018.
Application 15/232,892 is a continuation of application No. 14/678,114, filed on Apr. 3, 2015, granted, now 9,458,168, issued on Oct. 4, 2016.
Claims priority of provisional application 61/975,473, filed on Apr. 4, 2014.
Prior Publication US 2020/0377511 A1, Dec. 3, 2020
1. A pharmaceutical combination comprising 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, and a JAK1 inhibitor, or a pharmaceutically acceptable salt thereof.